DiaMedica Therapeutics Inc.

DMAC · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders27.8%

Institutions40.9%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	–	–	–	–	–	$500000
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$34.40M	-$26.68M	-$21.27M	-$14.00M	-$13.65M	-$12.70M	-$11.59M	-$6.76M
Operating income as a percentage of revenue.	–	–	–	–	–	–	–	-1352.2%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$32.77M	-$24.44M	-$19.38M	-$13.68M	-$13.59M	-$12.29M	-$10.65M	-$5.73M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.70	$-0.60	$-0.60	$-0.52	$-0.65	$-0.78	$0.00	$0.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$15.65M	$3.02M	$4.54M	$4.73M	$4.71M	$7.41M	$3.88M	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$61.37M	$46.34M	$54.16M	$34.40M	$45.55M	–	$9.05M	$18.34M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$56.10M	$40.70M	$51.10M	$31.80M	$44.00M	–	$7.62M	$17.02M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$29.10M	-$22.10M	-$18.70M	-$11.50M	-$12.30M	-$9.19M	-$9.10M	-$5.70M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$40000	$25000	$24000	$81000	$22000	$47000	$2000	$50000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$29.14M	-$22.13M	-$18.72M	-$11.58M	-$12.32M	-$9.23M	-$9.10M	-$5.75M

	You	Peer avg
P/E	–	3.3
Revenue Growth	–	-18.8%
ROE	-114.6%	-6.3%

DiaMedica Therapeutics Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison